Progestin-Only Injectables

What Are Progestin-Only Injectables?

- The injectable contraceptives depot medroxyprogesterone acetate (DMPA) and norethisterone enanthate (NET-EN) each contain a progestin like the natural hormone progesterone in a woman’s body. (In contrast, combined injectable contraceptives contain both estrogen and progestin and must be given monthly, see Chapter 5 – Monthly Injectables).
- They do not contain estrogen, and so can be used throughout breastfeeding, starting 6 weeks after giving birth, and by women who cannot use methods containing estrogen.
- After injection, the hormone is released slowly into the bloodstream.
- They are usually injected into the muscle (intramuscular injection). A newer formulation of DMPA can be injected just under the skin (subcutaneous injection). (See the box on DMPA for Subcutaneous Injection on p. 69).

Key Points for Providers and Clients

- **Bleeding changes are common but not harmful.** Typically there will be irregular bleeding for the first several months and then no monthly bleeding.
- **Return for injections regularly.** Coming back every 3 months (13 weeks) for DMPA or every 2 months (8 weeks) for NET-EN is important for greatest effectiveness. Subcutaneous DPMA can be self-injected.
- **The next injection can be as much as 4 weeks late for DMPA or 2 weeks late for NET-EN.** Even if it is later than this, the client may still be able to have the injection.
- **Gradual weight gain is common,** averaging 1–2 kg per year.
- **Return of fertility is often delayed.** It takes several months longer on average to become pregnant after stopping progestin-only injectables than after stopping other methods.
• DMPA, the most widely used progestin-only injectable, is also known in its intramuscular form as “the shot”, “the jab”, the injection, Depo, Depo-Provera, and Petogen. The subcutaneous version (DMPA-SC) comes in two forms: the Uniject injection system currently marketed under the name Sayana Press; and the prefilled single-dose disposable hypodermic syringes marketed as Depo-SubQ Provera 104. The Uniject system allows DMPA-SC to be easily self-injected by clients who wish to do so.

• NET-EN is also known as Noristerat, Norigest, and Syngestal. (See the job aid entitled Comparing Injectables for differences between DMPA and NET-EN.)

• Progestin-only injectables work primarily by preventing the release of eggs from the ovaries (ovulation).

How Effective?

Effectiveness depends on getting injections regularly: Risk of pregnancy is greatest when a woman misses an injection.

• As commonly used, about 4 pregnancies would be expected per 100 women using progestin-only injectables over the first year. This means that 96 of every 100 women using injectables will not become pregnant.

• When women have injections on time, less than 1 pregnancy would be expected per 100 women using progestin-only injectables over the first year (specifically, just 2 pregnancies would be expected per 1,000 women using this method).

Return of fertility after injections are stopped: Fertility takes an average of about 4 months longer to return for DMPA and 1 month longer for NET-EN compared with most other methods (see Question 8 at the end of this chapter).

Protection against sexually transmitted infections (STIs): None.
Why Some Women Say They Like Progestin-Only Injectables

- Requires action only every 2 or 3 months. No daily pill-taking.
- Does not interfere with sex
- Private: No one else can tell that a woman is using contraception
- Stops monthly bleeding (for many women)
- May help women to gain weight

Side Effects, Health Benefits, and Health Risks

Side Effects
(see also Managing Any Problems, p. 89)
Most users report some changes in monthly bleeding.¹

- With DMPA, these typically include:
  - First 3 months:
    - Irregular bleeding
    - Prolonged bleeding
  - At and after 1 year:
    - No monthly bleeding
    - Infrequent bleeding
    - Irregular bleeding

- With NET-EN, bleeding patterns are less affected than with DMPA
  - First 6 months:
    - Fewer days of bleeding
  - After 1 year:
    - More likely to have monthly bleeding than DMPA users.

¹ For definitions of bleeding patterns, see “vaginal bleeding” in the Glossary.
Some users report the following side effects:
- Weight gain (see Question 5, p. 94)
- Headaches
- Dizziness
- Abdominal bloating and discomfort
- Mood changes

Other possible physical changes:
- Loss of bone density (largely reversible, see Question 11, p. 95)

**Health Benefits and Health Risks**

**Known Health Benefits**

**DMPA**

Helps protect against:
- Pregnancy and associated risks
- Cancer of the lining of the uterus (endometrial cancer)
- Uterine fibroids

May help protect against:
- Iron-deficiency anemia

Reduces:
- Sickle cell crises among women with sickle cell anemia
- Symptoms of endometriosis (pelvic pain, irregular bleeding)

**NET-EN**

Helps protect against:
- Pregnancy and associated risks
- Iron-deficiency anemia

**Known Health Risks**

None

---

2 NET-EN may also offer many of the other health benefits that DMPA offers, but this list of benefits includes only those for which there is available research evidence.
Progestin-Only Injectables

Progestin-only injectables:

- Can stop monthly bleeding, but this is not harmful and could help prevent anemia. It is similar to not having monthly bleeding during pregnancy; blood is not building up inside the woman.
- Are highly effective regardless of the bleeding pattern.
- Do not disrupt an existing pregnancy.
- Do not make women infertile.

Correcting Misunderstandings

(see also Questions and Answers, at the end of this chapter)

Progestin-only injectables:

- Can stop monthly bleeding, but this is not harmful and could help prevent anemia. It is similar to not having monthly bleeding during pregnancy; blood is not building up inside the woman.
- Are highly effective regardless of the bleeding pattern.
- Do not disrupt an existing pregnancy.
- Do not make women infertile.

Delivering Injectable Contraception in the Community

Injectable contraceptives are popular with many women. This method can be more widely available when it is offered in the community as well as in clinics.

Lay health workers, auxiliary nurses, pharmacists, and other community-based providers of injectables should be trained and able to give intramuscular injections safely. They should also be able to screen clients for pregnancy and for medical eligibility for different contraceptives. They can inform women about delayed return of fertility and common side effects, including irregular bleeding, no monthly bleeding, and weight gain, and explain the importance of dual protection if a woman is at risk

(Continued on next page)
for STIs, including HIV. They also can inform women about the range of methods available, including methods only available at a clinic. All providers of injectables need specific competency-based training and supportive supervision to carry out these tasks. WHO recommends specific monitoring and evaluation of the provision of injectables by lay health workers (see Who Provides Family Planning?, p. 400 in Chapter 26).

Prefilled syringes aid community-based programs

Prefilled single-dose, single-use injection devices make community and home delivery easier and faster because providers do not have to draw a measured dose into the syringe from a vial. Also, these devices cannot be reused, preventing the spread of infection. DMPA is available in a number of prefilled single-dose injection systems. DMPA for intramuscular injection (DMPA-IM) is available in auto-disable syringes. The newer subcutaneous DMPA formulation (DMPA-SC), which is suitable only for injection just under the skin, comes in both the Uniject injection system (under the brand name Sayana Press) and the prefilled single-dose conventional disposable hypodermic syringes (marketed as Depo-SubQ Provera 104) (see the box on DMPA for Subcutaneous Injection, on the previous page). DMPA-SC, particularly in the Uniject system, is likely to make delivery of DMPA injection in the community and at home easier. In fact, women can learn to inject themselves with this formulation (see Teaching Clients How to Self-Inject, pp. 83–86).

Working together, in communities and clinics

For success, clinic-based providers and community-based providers need to work together closely. Programs vary, but these are some ways that clinic-based providers can support community-based providers:

• Managing side effects (see Managing Any Problems, pp. 89–92)
• Using clinical judgment concerning medical eligibility in special cases (see Using Clinical Judgment in Special Cases, p. 74)
• Ruling out pregnancy in women who are more than 4 weeks late for a DMPA injection or more than 2 weeks late for a NET-EN injection (see Managing Late Injections, p. 88)
• Responding to the concerns of clients referred by the community-based providers.

The clinic can also serve as a “home” for the community-based providers, where they can go for resupply, for supervision, training, and advice, and to turn in their records.
Progestin-Only Injectables

Who Can and Cannot Use Progestin-Only Injectables

Safe and Suitable for Nearly All Women

Nearly all women can use progestin-only injectables safely and effectively, including women who:

- Have had children or have not had children
- Are married or are not married
- Are of any age, including adolescents and women over 40 years old
- Have just had an abortion or miscarriage
- Smoke cigarettes, regardless of age or the number of cigarettes smoked
- Are breastfeeding, starting as soon as 6 weeks after childbirth
- Are living with HIV, whether or not they are on antiretroviral therapy (see the box on Progestin-Only Injectables for Women Living With HIV, p. 74)
- Are at high risk of HIV, or other STIs.

Avoid Unnecessary Procedures

(see Importance of Selected Procedures in Chapter 26 – Family Planning Provision, p. 396)

Women can begin using progestin-only injectables:

- Without a pelvic examination
- Without any blood tests or other routine laboratory tests
- Without cervical cancer screening
- Without a breast examination
- Without a pregnancy test. A woman can begin using a progestin-only injectable at any time, even when she is not having monthly bleeding at the time, if it is reasonably certain she is not pregnant (see Pregnancy Checklist, inside back cover).

Blood pressure measurement is desirable before starting a hormonal method. However, where the risks of pregnancy are high and few methods are available, a woman should not be denied a hormonal method simply because her blood pressure cannot be measured. If possible, she can have her blood pressure measured later, at a time and place convenient for her.
Medical Eligibility Criteria for Use of Progestin-Only Injectables

Ask the client the questions below about known medical conditions. Examinations and tests are not necessary. If she answers “no” to all of the questions, then she can start progestin-only injectables if she wants. If she answers “yes” to a question, follow the instructions; in some cases she can still start progestin-only injectables.

1. Are you breastfeeding a baby less than 6 weeks old?
   - No
   - Yes The client can start using progestin-only injectables as soon as 6 weeks after childbirth (see “Fully or nearly fully breastfeeding” or “Partially breastfeeding”, in the section on When to Start, p. 76)

2. Do you have severe cirrhosis of the liver or severe liver tumor?
   - No
   - Yes If the client reports severe cirrhosis or severe liver tumor, such as liver cancer, do not provide progestin-only injectables. Help her choose a method without hormones.

3. Do you have high blood pressure?
   - No
   - Yes Check her blood pressure if possible.
     - If the client is currently being treated for high blood pressure and it is adequately controlled, or her blood pressure is below 160/100 mmHg, provide progestin-only injectables.
     - If systolic blood pressure is 160 mmHg or higher or diastolic blood pressure is 100 or higher, do not provide progestin-only injectables. Neither progestin-only injectables nor any methods containing estrogen are appropriate for the client; help her choose another method.
     - If the client reports having high blood pressure in the past, and you cannot check blood pressure, provide progestin-only injectables.

4. Have you had diabetes for more than 20 years or do you have damage to your arteries, vision, kidneys, or nervous system caused by diabetes?
   - No
   - Yes Do not provide progestin-only injectables. Neither progestin-only injectables nor any methods containing estrogen are appropriate for the client; help her choose another method.
5. Have you ever had a stroke, blood clot in your leg or lungs, heart attack, or other serious heart problems?

- No
- Yes If the client reports heart attack, heart disease due to blocked or narrowed arteries, or stroke, do not provide progestin-only injectables. Help her choose a different method that does not contain estrogen. If she reports a current blood clot in one of her legs (affecting deep veins, not superficial veins) or in a lung and she is not on anticoagulant therapy, help her choose a method without hormones.

6. Are you having vaginal bleeding that is unusual for you?

- No
- Yes If the client has unexplained vaginal bleeding that suggests pregnancy or an underlying medical condition, progestin-only injectables could make diagnosis and monitoring of any treatment more difficult. Help her choose another method to use until she has been evaluated and treated, but not implants or a copper-bearing or hormonal IUD. After treatment, re-evaluate the client’s eligibility for use of progestin-only injectables.

7. Do you have or have you ever had breast cancer?

- No
- Yes Do not provide progestin-only injectables. Help her choose a method without hormones.

8. Do you have several conditions that could increase your chances of heart disease (coronary artery disease) or stroke, such as high blood pressure and diabetes?

- No
- Yes Do not provide progestin-only injectables. Help the client choose a different method that does not contain estrogen.

Also, a woman should not use progestin-only injectables if she reports having lupus with positive (or unknown) antiphospholipid antibodies and is not on immunosuppressive treatment, or if she has severe thrombocytopenia. For complete classifications, see Appendix D – Medical Eligibility Criteria for Contraceptive Use.

Be sure to explain the health benefits as well as the potential risks and side effects associated with the client’s chosen method. Also, point out any conditions that would make the method inadvisable for use by that particular client.
Using Clinical Judgment in Special Cases

Usually, a woman with any of the conditions listed below should not use progestin-only injectables. In special circumstances, however, when other, more appropriate methods are not available or acceptable to her, a qualified provider who can carefully assess a specific woman’s condition and situation may decide that she can use progestin-only injectables. The provider needs to consider the severity of her condition and, for most conditions, whether she will have access to follow-up care.

- Breastfeeding and less than 6 weeks since giving birth (considering the risks of another pregnancy and that the woman may have limited further access to injectables)
- Severe high blood pressure (systolic 160 mm Hg or higher or diastolic 100 mm Hg or higher)
- Acute blood clot in deep veins of legs or lungs
- History of heart disease or current heart disease due to blocked or narrowed arteries (ischemic heart disease)
- History of stroke
- Multiple risk factors for arterial cardiovascular disease such as diabetes and high blood pressure
- Unexplained vaginal bleeding before evaluation for possible serious underlying condition
- Had breast cancer more than 5 years ago, and it has not returned
- Diabetes for more than 20 years, or damage to arteries, vision, kidneys, or nervous system caused by diabetes
- Severe cirrhosis of the liver or liver tumor
- Systemic lupus erythematosus with positive (or unknown) antiphospholipid antibodies and not on immunosuppressive treatment, or severe thrombocytopenia

Progestin-OnlyInjectables for Women Living With HIV

- Women who are living with HIV including those who are on antiretroviral therapy (ART) can safely use progestin-only injectables.
- The time between injections does not need to be shortened for women on ART.
- Urge these women to use condoms as well. Used consistently and correctly, condoms help prevent transmission of HIV and other STIs.
Providing Progestin-Only Injectables

When to Start

**IMPORTANT:** A woman can start injectables any time she wants if it is reasonably certain she is not pregnant. To be reasonably certain she is not pregnant, use the Pregnancy Checklist (see inside back cover).

<table>
<thead>
<tr>
<th>Woman’s situation</th>
<th>When to start</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Having menstrual cycles</strong></td>
<td>Any time of the month</td>
</tr>
<tr>
<td></td>
<td>• If it is within 7 days after the start of her monthly bleeding, she can start immediately and there is no need for a backup method.</td>
</tr>
<tr>
<td></td>
<td>• If it is more than 7 days after the start of her monthly bleeding, she can start any time it is reasonably certain she is not pregnant. She will need a backup method* for the first 7 days after the injection.</td>
</tr>
<tr>
<td></td>
<td>• If she is switching from an IUD, she can start immediately and there is no need for a backup method (see Switching From an IUD to Another Method, in Chapter 10 – Copper-Bearing Intrauterine Device, p. 182, and in Chapter 11 – Levonorgestrel IUD, p. 211).</td>
</tr>
<tr>
<td><strong>Switching from another hormonal method</strong></td>
<td>If she has been using the other hormonal method consistently and correctly or if it is otherwise reasonably certain she is not pregnant, she can start immediately (no need to wait for her next monthly bleeding) and there is no need for a backup method.</td>
</tr>
<tr>
<td></td>
<td>• If she is switching from another injectable, she can have the new injectable when the repeat injection would have been given. There is no need for a backup method.</td>
</tr>
</tbody>
</table>

* Backup methods include abstinence, male and female condoms, spermicides, and withdrawal. Tell her that spermicides and withdrawal are the least effective contraceptive methods. If possible, give her condoms.

(Continued on next page)
<table>
<thead>
<tr>
<th>Woman’s situation</th>
<th>When to start (continued)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fully or nearly fully breastfeeding</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Less than 6 months after giving birth</strong></td>
<td></td>
</tr>
<tr>
<td>• If she gave birth less than 6 weeks ago, delay her first injection until at least 6 weeks after giving birth.</td>
<td></td>
</tr>
<tr>
<td>• If her monthly bleeding has not returned, she can start injectables any time between 6 weeks and 6 months, if it is reasonably certain she is not pregnant. There is no need for a backup method.</td>
<td></td>
</tr>
<tr>
<td>• If her monthly bleeding has returned, she can start injectables as advised for women having menstrual cycles (see the first row of this table).</td>
<td></td>
</tr>
<tr>
<td><strong>More than 6 months after giving birth</strong></td>
<td></td>
</tr>
<tr>
<td>• If her monthly bleeding has not returned, she can start injectables any time if it is reasonably certain she is not pregnant. She will need a backup method* for the first 7 days after the injection.</td>
<td></td>
</tr>
<tr>
<td>• If her monthly bleeding has returned, she can start injectables as advised for women having menstrual cycles (see the first row of this table).</td>
<td></td>
</tr>
<tr>
<td><strong>Partially breastfeeding</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Less than 6 weeks after giving birth</strong></td>
<td></td>
</tr>
<tr>
<td>• Delay her first injection until at least 6 weeks after giving birth.</td>
<td></td>
</tr>
<tr>
<td><strong>More than 6 weeks after giving birth</strong></td>
<td></td>
</tr>
<tr>
<td>• If her monthly bleeding has not returned, she can start injectables any time if it is reasonably certain she is not pregnant.‡ She will need a backup method* for the first 7 days after the injection.</td>
<td></td>
</tr>
<tr>
<td>• If her monthly bleeding has returned, she can start injectables as advised for women having menstrual cycles (see the first row of this table).</td>
<td></td>
</tr>
</tbody>
</table>

* Backup methods include abstinence, male and female condoms, spermicides, and withdrawal. Tell her that spermicides and withdrawal are the least effective contraceptive methods. If possible, give her condoms.

‡ Where a visit 6 weeks after childbirth is routinely recommended and other opportunities to obtain contraception are limited, some providers and programs may give the first injection at the 6-week visit, without further evidence that the woman is not pregnant, if her monthly bleeding has not yet returned.
<table>
<thead>
<tr>
<th>Woman’s situation</th>
<th>When to start</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Not breastfeeding (after giving birth)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Less than 4 weeks after giving birth</strong></td>
<td>• She can start injectables at any time and there is no need for a backup method.</td>
</tr>
<tr>
<td><strong>More than 4 weeks after giving birth</strong></td>
<td>• <em>If her monthly bleeding has not returned</em>, she can start injectables any time if it is reasonably certain she is not pregnant.† She will need a backup method* for the first 7 days after the injection.</td>
</tr>
<tr>
<td></td>
<td>• <em>If her monthly bleeding has returned</em>, she can start injectables as advised for women having menstrual cycles (see the first row of this table).</td>
</tr>
<tr>
<td><strong>No monthly bleeding (not related to childbirth or breastfeeding)</strong></td>
<td>• She can start injectables any time if it is reasonably certain she is not pregnant. She will need a backup method* for the first 7 days after the injection.</td>
</tr>
<tr>
<td><strong>After miscarriage or abortion</strong></td>
<td>• <em>If she is starting within 7 days</em> after first- or second-trimester miscarriage or abortion, she can start immediately and there is no need for a backup method.</td>
</tr>
<tr>
<td></td>
<td>• <em>If it is more than 7 days</em> after first- or second-trimester miscarriage or abortion, she can start injectables any time if it is reasonably certain she is not pregnant. She will need a backup method* for the first 7 days after the injection.</td>
</tr>
<tr>
<td><strong>After taking emergency contraceptive pills (ECPs)</strong></td>
<td><strong>After taking progestin-only or combined ECPs:</strong></td>
</tr>
<tr>
<td></td>
<td>• She can start or restart injectables on the same days as taking the ECPs. <em>There is no need to wait for the next monthly bleeding to have the injection.</em> She will need a backup method* for the first 7 days after the injection.</td>
</tr>
<tr>
<td></td>
<td>• If she does not start immediately but returns for injectables, she can start at any time if it is reasonably certain she is not pregnant.</td>
</tr>
</tbody>
</table>

*(Continued on next page)*
When to start

**After taking ulipristal acetate (UPA) ECPs:**

- She can start or restart injectables on the 6th day after taking UPA-ECPs, so make an appointment for her to return for the injection on the 6th day or as soon as possible after that. *There is no need to wait for the next monthly bleeding to have the injection.* The progestin in the injectables and UPA interact with each other. If the injectable is started sooner, and both are thus present in the body, one or both of the medications may be less effective.

- She will need to use a backup method from the time she takes UPA-ECPs until 7 days after the injection.

- If she does not start on the 6th day but returns later for injectables, she may start at any time if it is reasonably certain she is not pregnant.

---

**Giving Advice on Side Effects**

**IMPORTANT:** Thorough counseling about bleeding changes and other side effects must be provided before starting a woman on progestin-only injectables. Counseling about bleeding changes may be the most important help a woman needs to enable her to keep using this method without concern.

**Describe the most important common side effects**

- For the first several months:
  - irregular bleeding, prolonged bleeding, frequent bleeding

- Later:
  - no monthly bleeding

- Other common side effects include weight gain (about 1–2 kg per year), headaches, and dizziness, among others.

**Explain about these side effects**

- Side effects are not signs of illness.
- Common, but some women do not have them.
- The client can come back for help if side effects bother her.
Giving Intramuscular Injection With a Conventional Syringe

1. Obtain 1 dose of injectable contraception, a needle, and syringe
   - DMPA: 150 mg
   - NET-EN: 200 mg
   - For each injection, use a prefilled single-use syringe and needle from a new, sealed package (within expiration date and not damaged), if available.
   - If a prefilled single-use syringe is not available, use single-dose vials. Check the expiration date on the vial. If using an open multidose vial, check that the vial is not leaking.
     - DMPA: Use a 2-ml syringe and a 21- to 23-gauge intramuscular needle.
     - NET-EN: Use a 2- or 5-ml syringe and a 19-gauge intramuscular needle. A narrower needle (21- to 23-gauge) can also be used.

2. Wash
   - Wash your hands with soap and water, if possible, and let them dry in the air.
   - If the injection site is dirty, wash it with soap and water.
   - There is no need to wipe the site with antiseptic.

If using a prefilled syringe, skip to step 5

3. Prepare vial
   - DMPA: Gently shake the vial.
   - NET-EN: Shaking the vial is not necessary.
   - There is no need to wipe the top of the vial with antiseptic.
   - If the vial is cold, warm to skin temperature before giving the injection.

4. Fill syringe
   - Pierce the top of the vial with a sterile needle and fill syringe with the proper dose.

(Continued on next page)
5. Inject formula

- Insert the needle deep into the hip (ventrogluteal muscle), the upper arm (deltoid muscle), or the buttocks (gluteal muscle, upper outer portion), whichever the woman prefers. Inject the contents of the syringe.

- Do not massage the injection site.

6. Dispose of disposable syringes and needles safely

- Do not recap, bend, or break needles before disposal.

- Place in a puncture-proof sharps container.

- Do no reuse disposable syringes and needles. They are meant to be destroyed after a single use. Because of their shape, they are very difficult to disinfect. Therefore, reuse might transmit diseases such as HIV and hepatitis.

- If reusable syringes and needles are used, they must be sterilized again after each use (see Infection Prevention in the Clinic, in Chapter 26 – Family Planning Provision, p. 404).
## Giving the Injection With Subcutaneous DMPA in Uniject (Sayana Press)

### 1. Gather the supplies

<table>
<thead>
<tr>
<th>Supplies include:</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Uniject prefilled injection device at room temperature that has not passed its expiration date</td>
</tr>
<tr>
<td>- Soap and clean water</td>
</tr>
<tr>
<td>- Cotton swabs or cotton balls, if available</td>
</tr>
<tr>
<td>- Safe puncture-proof container for sharps disposal</td>
</tr>
</tbody>
</table>

### 2. Wash

- Wash your hands with soap and water, if possible.
- Let your hands dry in the air.
- If the injection site is dirty, wash it with soap and water.
- There is no need to wipe the site with antiseptic.

### 3. Ask where the client wants the injection

You can give the injection just under the skin:
- In the back of the upper arm
- In the abdomen (but not at the navel)
- On the front of the thigh

![Injection sites](image)

### 4. Open the pouch

- Open the foil pouch and remove the device.

### 5. Mix the solution

- Hold the device by the port (see picture 1).
- Shake it hard for 30 seconds.
- Check that the solution is mixed (granules distributed throughout the solution) and there is no damage or leaking.

![Port, Cap, Reservoir, Needle](image)

1. Parts of Uniject device

*(Continued on next page)*
6. Close the gap

- Hold the device by the port.
- Hold the device with the needle pointed upward to avoid spilling the drug.
- Push the cap into the port (see part A of picture 2, below).
- Continue to push firmly until the gap between the cap and port is closed (see part B of picture 2, below).
- Take off the cap (see part C of picture 2, below).

7. Give the injection

- Gently pinch the skin at the injection site (see picture 3). This helps to make sure that the drug is injected into fatty tissue just under the skin and not into muscle.
- Holding the port, gently push the needle straight into the skin with the needle pointing down (never upward) until the port touches the skin.
- Squeeze the reservoir slowly. Take 5–7 seconds.
- Pull out the needle and then release the skin.
- Do not clean or massage the site after injecting.

8. Discard the used device

- Do not replace the cap.
- Place the device in the sharps disposal container.
Advice for the Client After Providing Injection

Give specific instructions
- Tell her not to massage the injection site.
- Tell the client the name of the injection.
- Agree on a date for her next injection and give her a paper with the date written on it.

Self-Injection Can Be an Option

Women can learn to inject themselves with the subcutaneous formulation of DMPA (DMPA-SC). Some women like self-injection better than injections by health workers. Self-injection may save women time and money. WHO recommends making self-administration of injectable contraception available as an additional approach to deliver injectable contraception to individuals of reproductive age.

Teaching Clients to Self-Inject

For clients who want to give themselves the injections, you can teach them how to do this. The following steps apply to self-injection with DMPA-SC in the Uniject device (marketed as Sayana Press).

1. **Discuss the plan for storage and disposal.**
   - **Storage.** Discuss where the client can safely store the devices for many months. They should be kept out of the reach of children and animals and in moderate temperatures (not in direct sunlight or in a refrigerator).
   - **Disposal.** Discuss how the client can dispose of the devices in a container that has a lid and cannot be punctured and which can be kept away from children. (Local programs should decide how to help women dispose of used needles.)

2. **Explain and show the client how to self-inject.** Show the client the device and describe its parts. (See pictures in the instructions, on the next pages.) Give her a copy of the instructions and pictures provided below, a similar instruction sheet, or a booklet of more detailed instructions.

Note: The instructions How to Give Yourself an Injection with Sayana Press starting on the next page can be copied and given to the client.

Continued on p. 86
# How to Give Yourself an Injection with Sayana Press

<table>
<thead>
<tr>
<th>Important steps</th>
<th>How to do it</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Choose a correct injection site</strong></td>
<td>Choose either: the belly (but not the navel) or The front of the thigh</td>
</tr>
<tr>
<td><strong>2. Hold the device and mix the solution</strong></td>
<td></td>
</tr>
<tr>
<td>1. Where to give yourself the injection</td>
<td></td>
</tr>
<tr>
<td>2. Mix the solution</td>
<td>After washing hands, open the pouch and take out the injection device. Hold the device by the port (not the cap) and shake it hard for about 30 seconds. Make sure the solution is completely mixed.</td>
</tr>
<tr>
<td><strong>3. Push the cap and the port together to close the gap</strong></td>
<td>Point the needle upward. Hold the cap with one hand and the port with the other hand. Press cap down firmly until the gap is closed.</td>
</tr>
<tr>
<td>Parts of Uniject device</td>
<td>Close gap Gap closed</td>
</tr>
<tr>
<td><strong>3. Close the gap</strong></td>
<td></td>
</tr>
</tbody>
</table>
### Important steps

<table>
<thead>
<tr>
<th>Step</th>
<th>Description</th>
</tr>
</thead>
</table>
| 4. Pinch your skin into a “tent” | - Take the cap off the needle. Hold the device by the port.  
  - With the other hand pinch about 4 cm (1½ inches) of skin. |
| 5. Put the needle into the skin, and squeeze the reservoir slowly | - Press the needle straight into the skin with the needle pointing downward.  
  - Press the needle in until the port touches the skin completely.  
  - Squeeze the reservoir slowly, for 5–7 seconds. |

| 6. Dispose of the needle safely | - Pull the needle out and then let go of the skin.  
  - Put the device in a disposal container that can be closed and cannot be punctured. |

| 7. Plan for your next injection | - Mark a calendar or other reminder for the same day of the month, 3 months from today.  
  - You can give yourself the next injection as early as 2 weeks before that date or as late as 4 weeks after.  
  - If more than 4 weeks late, use another contraceptive method and see a health worker.  
  - Make sure you have another device for the next injection and that it will not expire before then. |

---

If you need help or more injection devices, contact:

_________________________________________________________

at ______________________________________________________
Teaching Clients To Self-Inject (continued from p. 83)

instructions. Explain the important steps. Use a sample injection device and an injection model (instead of a human limb) to show the client how to do each step while helping the client follow along on the instruction sheet. (If an injection model is not available, you can use a condom filled with salt or sugar. Alternatively, you can use fruit or bread.)

3. **Ask the client to try it.** After you have demonstrated the steps of self-injection, ask the client to practice on the injection model with a Uniject device. Watch her and then discuss what went well and what did not. Answer her questions, and invite the client to keep practicing on the model until she can do all the steps correctly and feels ready to inject herself.

4. **Ask the woman to inject herself while you are watching.** When she has successfully done this, give her injection devices to take home so that she can inject herself every 3 months into the future. Make sure that she understands when her future injection dates are, and how to calculate those dates by noting the same day of the month every 3 months.

5. **Tell the client where to get more injection devices.** Invite her to contact you if she has any questions or problems with self-injection or with getting more injection devices.
Supporting New and Continuing Users

How Can a Partner Help?

The client’s partner is welcome to participate in counseling and learn about the method and what support he can give to his partner. A male partner can:

- Support his partner’s choice of progestin-only injectables
- Show understanding and support if she has side effects
- Help her to remember to get her next injection on time
- Help to make sure she has emergency contraceptive pills (ECPs) on hand in case she is late for an injection by more than 4 weeks for DMPA or more than 2 weeks for NET-EN
- Use condoms consistently in addition to the progestin-only injectable if he has an STI/HIV or thinks he may be at risk of an STI/HIV.

“Come Back Anytime”: Reasons to Return Before the Next Injection

Assure every client that she is welcome to come back any time—for example, if she has problems, questions, or wants another method; if she has a major change in health status; or if she thinks she might be pregnant.

General health advice

Anyone who suddenly feels that something is seriously wrong with her health should immediately seek medical care from a nurse or doctor. Her contraceptive method is most likely not the cause of the condition, but she should tell the health worker what method she is using.

Planning the Next Injection

1. Agree on a date for the client’s next injection in 3 months (13 weeks) for DMPA, or in 2 months (8 weeks) for NET-EN. Give her a paper with the date written on it (or dates, if she is self-injecting and taking home more than 1 injection device). Discuss how to remember the date of her next injection, perhaps putting it on the same date as a holiday or other event, or circling the date on a calendar.
2. Ask her to try to come on the agreed date. With DMPA, she may come up to 4 weeks after the scheduled injection date and still get an injection. With NET-EN, she may come up to 2 weeks after the scheduled injection date and still get an injection. With either DMPA or NET-EN, she can come up to 2 weeks before the scheduled injection date.

3. She should come back no matter how late she is for her next injection. See Managing Late Injections, below.

**Repeat Injection Visits**

1. Ask how the client is doing with the method and whether she is satisfied. Ask if she has any questions or anything she’d like to discuss.

2. In particular, ask if she is concerned about bleeding changes. Give her any information or help that she needs (see Managing Any Problems, on the next page).

3. Give her the injection. Injection of DMPA can be given up to 4 weeks late. Injection of NET-EN can be given up to 2 weeks late. Either can be given up to 2 weeks early (See Question 14, at the end of this chapter).

4. Plan for her next injection. Agree on a date for her next injection (in 3 months for DMPA, 2 months for NET-EN). Remind her that she should try to come on that date (at the scheduled appointment, if there is one), but tell her that she should come back no matter how late she is. (See Managing Late Injections, below).

5. Every year or so, check her blood pressure if possible (see Medical Eligibility Criteria for Use of Progestin-Only Injectables, Question 3, in this chapter, p. 72).

6. Ask long-term users of progestin-only injectables if they have had any new health problems. Address problems as appropriate. See New Problems That May Require Switching Methods, p. 91.

7. Ask long-term clients about any major life changes that may affect family planning needs – particularly plans for having children and STI/HIV risk. Follow up as needed.

**Managing Late Injections**

- If the client is up to 4 weeks late for a repeat injection of DMPA, or up to 2 weeks late for a repeat injection of NET-EN, she can receive her next injection. There is no need for tests, evaluation, or a backup method.

- A client who is more than 4 weeks late for DMPA or more than 2 weeks late for NET-EN can receive her next injection, if:
  - she has not had sex since 2 weeks after the scheduled date of her injection, or
– she has used a backup method or has taken ECPs after any unprotected sex since 2 weeks after the scheduled date of her injection, or
– she is fully or nearly fully breastfeeding and she gave birth less than 6 months ago.

However, in all three cases she will need a backup method for the first 7 days after the injection.

• If the client is more than 4 weeks late for DMPA or more than 2 weeks late for NET-EN and she does not meet any of these three criteria, additional steps can be taken to be reasonably certain she is not pregnant (see the job aid, Ruling Out Pregnancy). These steps are helpful because many women who have been using progestin-only injectables will have no monthly bleeding for at least a few months, even after discontinuation. Thus, asking her to come back during her next monthly bleeding means her next injection could be unnecessarily delayed and she may be left without contraceptive protection.

• Discuss the client’s reasons for being late for the repeat injection and explore solutions. Remind her that she should keep trying to come back every 3 months for DMPA, or every 2 months for NET-EN. If coming back on time is often a problem, discuss the option of self-injection with DMPA-SC, and discuss using a backup method when she is late for her next injection, taking ECPs, or choosing another method, such as an implant or IUD.

Managing Any Problems

Problems Reported as Side Effects

These problems may or may not be due to the progestin-only injectables but they affect women’s satisfaction and use of this method and therefore deserve the provider’s attention. The following information advises how to address any reported side effects and specific conditions.

Any reported side effects

• Listen to the client’s concerns, give her advice and support, and, if appropriate, treat the condition. Make sure she understands the advice and agrees.

• Offer to help her choose another method—now, if she wishes, or if problems cannot be overcome.
No monthly bleeding

- Reassure the client that most women using progestin-only injectables stop having monthly bleeding over time, and this is not harmful. There is no need to lose blood every month; blood is not building up inside her. It is similar to not having monthly bleeding during pregnancy. It does not mean she has become infertile. Some women are happy to be free from monthly bleeding, when they understand that it is not harmful.

- If not having monthly bleeding bothers the woman, she may want to switch to monthly (combined) injectables, if available (see Chapter 5).

Irregular bleeding (bleeding at unexpected times)

- Reassure her that many women using progestin-only injectables experience irregular bleeding. It is not harmful and usually becomes less or stops after the first few months of use.

- For modest short-term relief, she can take 500 mg mefenamic acid twice daily after meals for 5 days, or 40 mg of valdecoxib once daily for 5 days, beginning when irregular bleeding starts.

- If irregular bleeding continues or starts after several months of normal or no monthly bleeding, or you suspect that something may be wrong for other reasons, consider underlying conditions unrelated to method use (see the row on “Unexplained vaginal bleeding”, p. 92).

Weight gain

- Review the client’s diet with her and counsel as needed.

Abdominal bloating and discomfort

- Consider locally available remedies.

Heavy or prolonged bleeding (twice as much as usual or longer than 8 days)

- Reassure the client that some women using progestin-only injectables experience heavy or prolonged bleeding. It is not harmful and usually becomes less or stops after a few months.

- For modest short-term relief she can try (one at a time), beginning when heavy bleeding starts:
  - 500 mg mefenamic acid twice daily after meals for 5 days
  - 40 mg of valdecoxib daily for 5 days
  - 50 µg ethinyl estradiol daily for 21 days
• If bleeding becomes a health threat or if the woman wants, help her choose a different method. In the meantime, she can use one of the treatments listed above to help reduce bleeding.

• To help prevent anemia, suggest she take iron tablets and tell her it is important to eat foods containing iron, such as meat and poultry (especially beef and chicken liver), fish, green leafy vegetables, and legumes (beans, bean curd, lentils, and peas).

• If heavy or prolonged bleeding continues or starts after several months of normal or no monthly bleeding, or you suspect that something may be wrong for other reasons, consider underlying conditions unrelated to method use (see the row on the next page on “Unexplained vaginal bleeding”).

**Ordinary headaches (nonmigrainous)**

• Suggest aspirin (325–650 mg), ibuprofen (200–400 mg), paracetamol (325–1,000 mg), or other pain reliever.

• Any headaches that get worse or occur more often during use of injectables should be evaluated.

**Mood changes or changes in sex drive**

• Ask the client about changes in her life that could affect her mood or sex drive, including changes in her relationship with her partner. Give support as appropriate.

• Clients who have serious mood changes such as major depression should be referred for care.

• Consider locally available remedies.

**Dizziness**

• Consider locally available remedies.

---

**New Problems That May Require Switching Methods**

These problems also may or may not be due to the use of progestin-only injectables.

**Migrainous headaches** (see the job aid on Identifying Migraine Headaches and Auras, pp. 458–460)

• If the client has migraine headaches without aura, she can continue to use the method if she wishes.

• If she has a migraine aura, do not give the injection. Help her choose a method without hormones.
Unexplained vaginal bleeding (that suggests a medical condition not related to the method)

- Refer or evaluate the client by history and pelvic examination. Diagnose and treat as appropriate.
- If no cause of bleeding can be found, consider stopping progestin-only injectables to make diagnosis easier. Provide another method of her choice (but not an implant or copper-bearing or hormonal IUD) to use until the condition is evaluated and treated.
- If bleeding is caused by an STI or pelvic inflammatory disease, she can continue using progestin-only injectables during treatment.

Certain serious health conditions (suspected blocked or narrowed arteries, serious liver disease, severe high blood pressure, blood clots in deep veins or legs or lungs, stroke, breast cancer, or damage to arteries, vision, kidneys, or nervous system caused by diabetes). See Appendix B – Signs and Symptoms of Serious Health Conditions.

- Do not give the next injection.
- Give the client a backup method to use until the condition is evaluated.
- Refer the client for diagnosis and care if she is not already under care.

Suspected pregnancy

- Assess the client for pregnancy.
- Stop injections if pregnancy is confirmed.
- There are no known risks to a fetus conceived while a woman is using injectables (see Question 12) or to a woman who receives an injection while pregnant.
Questions and Answers About Progestin-Only Injectables

1. **Can women at risk for sexually transmitted infections (STIs) use progestin-only injectables?**

   Yes. Women at risk for STIs can use progestin-only injectables. The few studies available have found that women using DMPA were more likely to acquire chlamydia than women not using hormonal contraception. The reason for this difference is not known. There are few studies available on the use of NET-EN and STIs. Like anyone else at risk for STIs, a user of progestin-only injectables who may be at risk for STIs should be advised to use condoms correctly and consistently with every sex act—this will reduce the risk of becoming infected with an STI.

2. **Can women at high risk for HIV use progestin-only injectables?**

   Yes. Except for using spermicides containing nonoxynol-9 (alone or with a diaphragm), women at high risk of HIV infection can use any contraceptive method, including progestin-only injectables (see Chapter 16 – Spermicides and Diaphragms). More detailed information on the topic is provided in Chapter 23 – Family Planning For Adolescents and Women at High Risk for HIV, including the importance of integrating HIV testing services into family planning care in settings where risk of HIV is high.

3. **If a woman does not have monthly bleeding while using progestin-only injectables, does this mean that she is pregnant?**

   Probably not, especially if she is breastfeeding. Eventually, most women using progestin-only injectables will not have monthly bleeding. If a woman has been getting her injections on time, she is probably not pregnant and can keep using injectables. If she is still worried after being reassured, she can be offered a pregnancy test, if available, or referred for one. If not having monthly bleeding bothers her, switching to a different method may help.

4. **Can a woman who is breastfeeding safely use progestin-only injectables?**

   Yes. This is a good choice for a breastfeeding mother who wants a hormonal method. Progestin-only injectables are safe for both the mother and the baby starting as early as 6 weeks after childbirth. They do not affect milk production.
5. **How much weight do women gain when they use progestin-only injectables?**

Women gain an average of 1–2 kg per year when using DMPA. Some of the weight increase may be the usual weight that people gain as they age. Some women, particularly overweight adolescents, have gained much more than 1–2 kg per year. At the same time, some users of progestin-only injectables lose weight or have no significant change in weight. Asian women in particular do not tend to gain weight when using DMPA.

6. **Do DMPA and NET-EN cause abortion?**

No. Research on progestin-only injectables finds that they do not disrupt an existing pregnancy. They should not be used to try to cause an abortion; they will not cause abortion.

7. **Do progestin-only injectables make a woman infertile?**

No. There may be a delay in regaining fertility after stopping progestin-only injectables, but in time the woman will be able to become pregnant as before, although fertility decreases as women get older. The bleeding pattern a woman had before she used progestin-only injectables generally returns several months after the last injection even if she had no monthly bleeding while using injectables.

8. **How long does it take to become pregnant after stopping DMPA or NET-EN?**

Women who stop using DMPA wait about 4 months longer on average to become pregnant than women who have used other methods. This means they become pregnant on average 10 months after their last injection. Women who stop using NET-EN wait about 1 month longer on average to become pregnant than women who have used other methods, or 6 months after their last injection. Since these are averages, a woman should not be worried if she has not become pregnant even as much as 12 months after stopping use. The length of time a woman has used injectables makes no difference to how quickly she becomes pregnant once she stops having injections.

After stopping progestin-only injectables, a woman may ovulate before her monthly bleeding returns and thus can become pregnant. If she wants to continue avoiding pregnancy, she should start another method before monthly bleeding returns.

9. **Does DMPA cause cancer?**

No. Many studies show that DMPA does not cause cancer. In fact, DMPA use helps protect against cancer of the lining of the uterus (endometrial cancer). Findings of a few studies on DMPA use and breast cancer are similar to findings on the use of combined oral contraceptives (pills): women using DMPA were slightly more likely to be diagnosed with breast cancer.
cancer while using DMPA or within 10 years after they stopped. It is unclear whether these findings are explained by earlier detection of existing breast cancers among DMPA users (for example, due to more frequent contact with health workers) or by a biologic effect of DMPA on breast cancer.

A few studies on DMPA use and cervical cancer suggest that there may be a slightly increased risk of cervical cancer among women using DMPA for 5 years or more. Cervical cancer cannot develop because of DMPA alone, however. It is caused by persistent infection with human papillomavirus (see the section on Cervical Cancer in Chapter 22, pp. 351–354). Little information is available about NET-EN. It is considered to be as safe as DMPA and other contraceptive methods containing only a progestin, such as progestin-only pills and implants.

10. **Can a woman switch from one progestin-only injectable to another?**

Switching injectables (from DMPA to NET-EN or vice versa) is safe, and it does not decrease effectiveness. If switching is necessary due to shortages of supplies, the first injection of the new injectable should be given when the next injection of the old formulation would have been given. Clients need to be told that they are switching, the name of the new injectable, and its injection schedule.

11. **How does DMPA affect bone density?**

During use, DMPA decreases bone mineral density slightly. This may increase the risk of developing osteoporosis and possibly also increase the risk of having bone fractures later, after menopause. WHO has concluded that this decrease in bone density does not place age or time limits on the use of DMPA.

12. **Do progestin-only injectables cause birth defects? Will the fetus be harmed if a woman accidentally uses progestin-only injectables while she is pregnant?**

No. Good evidence shows that progestin-only injectables will not cause birth defects and will not otherwise harm the fetus if a woman becomes pregnant while using progestin-only injectables or accidentally starts injectables when she is already pregnant.

13. **Do progestin-only injectables lower women’s mood or sex drive?**

Generally, no. Some women using injectables report these complaints, but the great majority of users do not report any such changes. It is difficult to tell whether such changes are due to progestin-only injectables or to other reasons. Providers can help a client with these problems (see “Mood changes or changes in sex drive”, in the section of this chapter on Managing Any Problems, p. 91). There is no evidence that progestin-only injectables affect women’s sexual behavior.
14. What if a woman returns for her next injection late?

A woman can have her next DMPA injection even if she is up to 4 weeks late, without the need for further evidence that she is not pregnant. A woman can receive her next NET-EN injection if she is up to 2 weeks late. Some women return even later for their repeat injection; in such cases providers can use the instructions on Ruling Out Pregnancy (p. 461), and if pregnancy can be ruled out then the injection can be given and the woman should use a backup method for the next 7 days. Whether a woman is late for reinjection or not, her next injection of DMPA should be planned for 3 months (13 weeks) later, or her next injection of NET-EN should be planned for 2 months (8 weeks) later, as usual.

When a Woman Can Have Her Next Injection of DMPA or NET-EN